Evidence map›Paper›PMID 33177062›Full record

ArticleCancer research2021

Optimized Doxorubicin Chemotherapy for Diffuse Large B-cell Lymphoma Exploits Nanocarrier Delivery to Transferrin Receptors.

Artavazd Arumov, Piumi Y Liyanage, Asaad Trabolsi, Evan R Roberts, Lingxiao Li, Braulio C L B Ferreira, Zhen Gao, Yuguang Ban, Austin D Newsam, Melissa W Taggart and 4 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Artavazd Arumov *Sheila and David Fuente Graduate Program in Cancer Biology, University of Miami Miller School of Medicine, Miami, Florida.ORCID https://orcid.org/0000-0002-9520-2777
Piumi Y Liyanage *Department of Chemistry, University of Miami, Coral Gables, Florida.
Asaad TrabolsiSylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida.
Evan R RobertsSylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida.
Lingxiao LiSylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida.
Braulio C L B FerreiraDepartment of Chemistry, University of Miami, Coral Gables, Florida.ORCID https://orcid.org/0000-0001-8242-0399
Zhen GaoBiostatistics and Bioinformatics Core Shared Resource, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida.
Yuguang BanBiostatistics and Bioinformatics Core Shared Resource, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida.
Austin D NewsamMedical Scientist Training Program, University of Miami Miller School of Medicine, Miami, Florida.
Melissa W TaggartDepartment of Pathology, MD Anderson Cancer Center, Houston, Texas.
Francisco VegaDepartment of Hematopathology, MD Anderson Cancer Center, Houston, Texas.ORCID https://orcid.org/0000-0001-5956-452X
Daniel BilbaoSylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida.
Roger M Leblanc *Department of Chemistry, University of Miami, Coral Gables, Florida. jschatz@med.maimi.edu rml@miami.edu.
Jonathan H Schatz *Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida. jschatz@med.maimi.edu rml@miami.edu.ORCID https://orcid.org/0000-0003-1842-228X
University of Miami · USSylvester Comprehensive Cancer Center · USThe University of Texas MD Anderson Cancer Center · US

Funding

Tumor Biology Research ProgramP30CA240139 · NCI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI Daniel Bilbao · 2019 to 2026
$24.1M
Medical Scientist Training ProgramT32GM112601 · NIGMS · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI LEMMON, SANDRA K. · 2017 to 2021
$1.9M
NIGMS NIH HHS T32 GM112601
6 · The paper itself

Abstract

New treatments are needed to address persistent unmet clinical needs for diffuse large B-cell lymphoma (DLBCL). Overexpression of transferrin receptor 1 (TFR1) is common across cancer and permits cell-surface targeting of specific therapies in preclinical and clinical studies of various solid tumors. Here, we developed novel nanocarrier delivery of chemotherapy via TFR1-mediated endocytosis, assessing this target for the first time in DLBCL. Analysis of published datasets showed novel association of increased TFR1 expression with high-risk DLBCL cases. Carbon-nitride dots (CND) are emerging nanoparticles with excellent

Indexed as

AnimalsAntibiotics, AntineoplasticAntigens, CDAntineoplastic Combined Chemotherapy ProtocolsApoptosisCell Line, TumorCell NucleusCell SurvivalCyclophosphamideDNA Breaks, Double-StrandedDoxorubicinEndocytosisLymphoma, Large B-Cell, DiffuseMaleMiceMice, Inbred NODAntibiotics, AntineoplasticAntigens, CDCD71 antigenCyclophosphamideDoxorubicinNanoconjugatesPrednisoneR-CHOP protocolReceptors, TransferrinRituximabTfrc protein, mouseTransferrinVincristine

Identifiers

PMID33177062
PMCPMC9177130
OpenAlexW3103251699

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.